不同频率脉冲电磁场对人卵巢癌SKOV3细胞增殖、凋亡及迁移的影响

Effect of Pulsed Electromagnetic Field with Different Frequencies on the Proliferation,Apoptosis and Migration of Human Ovarian Cancer Cells

研究不同频率的脉冲电磁场(PEMF)对人卵巢癌SKOV3细胞增殖、凋亡和迁移的影响,为PEMF治疗或预防卵巢癌切除术后发生骨质疏松患者的安全性提供实验参考数据。分别对体外培养的人SKOV3细胞施加不同频率(8、16、32和64Hz)、固定强度为1mT的PEMF,2次/d,30min/次,间隔12h,共3d,以未施加PEMF的细胞作为对照组。分别采用EdU荧光法、Annexin V-FITC荧光法和划痕实验检测SKOV3细胞增殖、凋亡及迁移的情况。结果:频率8Hz的PEMF能明显抑制SKOV3细胞的增殖,并诱导其凋亡。频率8Hz和32Hz的PEMF能明显促进人卵巢癌细胞SKOV3的迁移,而频率16Hz的PEMF却明显地抑制SKOV3细胞的迁移。提示不同频率的PEMF对人卵巢癌细胞SKOV3增殖、凋亡及迁移的影响不同。在临床中对于卵巢癌切除术后的骨质疏松患者,应当慎重考虑PEMF治疗的安全性,并严格选择治疗参数。

Pulsed electromagnetic field（PEMF）,a non-invasive physical treatment modality,is now used clinically to promote bone formation for osteoporosis.The patients after ectomy of ovarian cancer are easily complicated with osteoporosis.However,the safety parameters of PEMF treatment for the osteoporosis patients after resection of ovarian cancer remain unknown.Therefore,this study was designed to examine the effect of different frequency of PEMF on the proliferation,apoptosis and migration of human ovarian cancer cells（SKOV3 cells）.Cultured SKOV3 cells were exposed to PEMF stimulation daily with radiation of 8Hz,16Hz,32Hz and 64Hz,respectively.We used sinusoidal waves with strength of 1mT,twice a day with an interval of 12 hours.An exposure to the waves lasted 30 minutes,for 3 days,with those no PEMF stimulation serving as the control.The proliferation of cells was detected using EdU assay,and the apoptosis of cell was assessed with Annexin V-FITC fluorescence.The migration of cells was measured with the scratch wound assay.The data showed that exposure to PEMF of 1mT,8Hz for 3days could significantly inhibit the proliferation of SKOV3 cells and induce the apoptosis of the cells.The migrated distance and number were increased by 1mT,8Hz or 32Hz PEMF stimulation,but decreased by 1mT,16Hz treatment.The results suggested that we should be careful about the safety of PEMF treatment and strictly choose the optical parameters in preventing or treating the osteoporosis of the patients after resection of ovarian cancer.